Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 2/20 | 0.41 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470166 | 1.00 | PLA2G10 (0.41) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 | |
| SCHEMBL27147241 | 1.00 | PLA2G10 (0.41) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 | |
| SCHEMBL10063507 | 0.92 | HSD17B10 (0.42) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 | |
| SCHEMBL13160713 | 0.92 | PLA2G10 (0.40) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 | |
| SCHEMBL29341696 | 0.92 | KMT2A (0.41) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 | |
| SCHEMBL16749946 | 0.92 | HSD17B10 (0.42) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 | |
| SCHEMBL1041478 | 0.92 | HSD17B10 (0.42) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 | |
| SCHEMBL14680626 | 0.92 | PLA2G10 (0.38) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 | |
| SCHEMBL6450457 | 0.92 | CHRM2 (0.38) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 | |
| SCHEMBL13659005 | 0.92 | PLA2G10 (0.40) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234450-A1 | Molecular targeting agents | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2010-09-16 | — | — | US | disclosed |
| US-6995247-B2 | Ac-HEHA and related compounds, methods of synthesis and methods of use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-02-07 | — | — | US | disclosed |
| US-20040184991-A1 | Ac-HEHA and related compounds, methods of synthesis and methods of use | THE GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARY, DPT. OF HEALTH AND HUMAN SERVICES | 2004-09-23 | — | — | US | disclosed |
| US-6696551-B1 | RADIOIMMUNOTHERAPY, DECONTAMINATION AND DETOXIFICATION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234450-A1 | Molecular targeting agents | CD2BP2, CD47, ANXA6 | PLA2G10 4240/4885PLA2G5 3725/4885CHRM2 4849/4885 |
| US-20040184991-A1 | Ac-HEHA and related compounds, methods of synthesis and methods of use | APEH, DOHH, DDAH1 | PLA2G10 3019/4885PLA2G5 2400/4885CHRM2 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.